Zendesk Shares Traded Up 50% After-Hours Following Wall Street Journal Report That Co is Close to a Takeover Deal With Group Including Hellman & Friedman and Permira

https://www.wsj.com/articles/zendesk-close-to-striking-buyout-deal-with-group-including-hellman-friedman-and-permira-sources-say-11656021982

byCharles Gross

June 23, 2022

1 minute read

https://www.wsj.com/articles/zendesk-close-to-striking-buyout-deal-with-group-including-hellman-friedman-and-permira-sources-say-11656021982

Will The Ethereum-Bitcoin ‘Flippening’ Happen During This Cycle? Here’s What The Chart Says

By Melanie Schaffer

November 23, 5:48 PM

Ethereum (CRYPTO: ETH) broke up bullishly from a daily inside bar at 10 a.m. EST on Tuesday and by midafternoon was attempting to hold above Monday’s high-of-day price.

BTC

JP Morgan Maintains Overweight on Hydrofarm Holdings Group, Lowers Price Target to $22

By Benzinga Newsdesk

March 2, 11:39 AM

JP Morgan analyst Andrea Teixeira maintains Hydrofarm Holdings Group (NASDAQ:HYFM) with a Overweight and lowers the price target from $27 to $22.

HYFM

September Cass Data Underscores Stalled Shipments; Expenditures Surge

By FreightWaves

October 13, 2:30 PM

September data from Cass Information Systems showed shipments fell victim to supply chain and capacity constraints while expenditures, a proxy for pricing, surged forward.

CASS

Cantor Fitzgerald Initiates Coverage On Clarus Therapeutics Hldgs with Overweight Rating, Announces Price Target of $20

By Benzinga Newsdesk

September 20, 7:17 AM

Cantor Fitzgerald analyst Louise Chen initiates coverage on Clarus Therapeutics Hldgs (NASDAQ:CRXT) with a Overweight rating and announces Price Target of $20.

CRXT

Zendesk Shares Traded Up 50% After-Hours Following Wall Street Journal Report That Co is Close to a Takeover Deal With Group Including Hellman & Friedman and Permira

Related Posts

Will The Ethereum-Bitcoin ‘Flippening’ Happen During This Cycle? Here’s What The Chart Says

JP Morgan Maintains Overweight on Hydrofarm Holdings Group, Lowers Price Target to $22

September Cass Data Underscores Stalled Shipments; Expenditures Surge

Cantor Fitzgerald Initiates Coverage On Clarus Therapeutics Hldgs with Overweight Rating, Announces Price Target of $20